From an investor on another board:
*Going to be in 7 largest markets on Amazon EU in Q1 2022 (UK, Germany, France, Netherlands Sweden ect...) targeting 300 million people
*In talks with dozens of US retailers representing a point of no less than 30,000 points of sales
*Walmart and Kroger in a week or two
*Already producing Else for Canada in December to start selling in Q1 2022
*China is 45% of all global baby food market, 2022 (in talks with the largest e-commerce in China, announcing soon.)
*Pilot study, Else improves growth in children, GI symptoms, bowel movements improved up to 85% to 100% recovery)- they get to put results on the product!
*reaching 80,000 pediatricians to create growth engine for Else, started a month ago
*"Empire's take time to build" - CEO
*"Big things happening in 2022" -CEO
*2021 "was a year of laying the foundation for growth"
*"Very profitable in next 2-3 years"
* NASDAQ uplisting dependent on growth first and maybe next year...
*listed on TSX in CANADA Jan 20, 2022
*they will be diluting again, they have 23 million in cash right now =(
*lumping issues completely resolved on kids, changed instructions on toddler formula on how to dissolve powder
*FDA approval - clinical trial starts March 2022, ends in Q3 2023 (yikes, but okay)
*inflation hasn't affected their suppliers for almonds, tapioca, and buckwheat
*shipping has gone up but not dramatic enough to hurt Else
*Amazon EU will be smooth because they have had practice with Amazon US
*Else will be cash positive most likely 2-3 years from now
*30-40 SKUs dropping next year, US 11 SKUS, EU 11 SKUs, Canada, China
*expanding scientific advisory board, even more, to help get permit from the FDA
*No plans to split shares on uplisting
*They are making prototypes on Else bars (it's in the works)
*Else does not want to be a manufacturing company but they will own their own equipment.
*Airing a commercial in Q1 2022, once more SKUS come out (want to be on as many shelves as possible before TV)
*gross margins now are low 30's and are anticipating low 50's by 2024
*China's marketing strategy will be more on functionality, digestible, and gentle the formula is. China's babies are more prone to allergic and intolerance to dairy is greater than anywhere else in the western world
*they are going to partner with someone in China and create a team to market there, they also will work on products specifically for China down the road
*Europe, start with Amazon, then possibly getting into the pharmacy space there (Nice!)
*They have direct communication with Whole Foods in the US, they are planning to get there very soon
*Else has about 30-32 total employees
*partnering with the largest almond grower in CA(Else has its own orchard there), no limitation of almonds as far as next 5 years time
*Yes on strategic partnerships on the horizon, she can't talk about it
*no revenue guidance because they haven't had time to trend the velocity, and they need time to get to a revenue trend and need more data and selling products longer
*If you made it all the way to the end of this, give it a LIKE!
